{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.91","upperLimit":"3.91","value":"2.04"},{"groupId":"OG001","lowerLimit":"3.61","upperLimit":"5.75","value":"3.91"},{"groupId":"OG002","lowerLimit":"4.21","upperLimit":"6.31","value":"5.62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"53"}],"units":"Participants"}],"description":"PFS was defined as time from randomization until disease progression or death from any cause, whichever occurred first, for all participants. Progression was assessed using RECIST v1.1 per BICR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received investigator's choice of trifluridine and tipiracil or regorafenib. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.","id":"OG000","title":"Trifluridine and Tipiracil or Regorafenib"},{"description":"Participants received sotorasib 240 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.","id":"OG001","title":"Sotorasib 240 mg + Panitumumab"},{"description":"Participants received sotorasib 960 mg QD in combination with panitumumab. Treatment continued until progressive disease, intolerance to treatment necessitating treatment discontinuation, need for other anticancer therapy, withdrawal of consent, or death.","id":"OG002","title":"Sotorasib 960 mg + Panitumumab"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization until DCO or death; median (min, max) time on trial was 6.23 (0.1, 14.0) months","title":"Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR","type":"PRIMARY","unitOfMeasure":"months"}